|
HIV Vaccines: Maintaining the Momentum
|
|
CAHR 2016 Vaccine Research Plenary
Drs. Marc Oulette (CIHR Institute of Infection and Immunity), Jamie Mann (University of Western Ontario), and Gary Kobinger (Laval University) will be sharing their insights on vaccine research and development at CAHR 2016. The plenary will be held on May 13 as a special session to the conference, and will be moderated by Dr. Jonathan Angel from the Ottawa Hospital Research Institute and Dr. Michael Grant from Memorial University.
VIEW PROGRAM
|
| |
|
Global HIV Vaccine Enterprise
Innovative Uses of Technology in HIV Clinical Trials
April 14, 2016 | 8:30 am – 5:00 pm Eastern Time
Experts from various backgrounds will come together to present and discuss their experience with novel uses of technologies to facilitate or accelerate the conduct of clinical trials. Focusing on the use of mHealth (including SMS messaging), paperless workflow, and biometric devices, this one day meeting will consider the impact these technologies may have on trial design, data collection and analysis, regulatory and ethical challenges, and data security concerns. In addition to renewing past experience, the meeting will also consider “the next generation” of potentially promising technologies.
MORE INFORMATION
|
| |
|
Microbial translocation and microbiome dysbiosis in HIV-associated immune activation.
Curr Opin HIV AIDS. 2016 Mar;11(2):182-90. doi: 10.1097/COH.0000000000000234.
Zevin AS, McKinnon L, Burgener A, Klatt NR.
Microbes in HIV are likely playing a large role in contributing to HIV pathogenesis, morbidities and mortality. Two major disruptions to microbial systems in HIV infection include microbial translocation and microbiome dysbiosis. Microbial translocation occurs when the bacteria (or bacterial products) that should be in the lumen of the intestine translocate across the tight epithelial barrier into systemic circulation, where they contribute to inflammation and pathogenesis. This is associated with poorer health outcomes in HIV-infected individuals.
READ MORE
HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.
Trends Immunol. 2016 Mar;37(3):221-32. doi: 10.1016/j.it.2016.01.007. Epub 2016 Feb 9.
De Taeye SW, Moore JP, Sanders RW.
The identification of multiple broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) trimer has facilitated its structural characterization and guided Env immunogen design. Several recent studies constitute progress in utilizing this knowledge for the development of an HIV-1 vaccine that induces bNAbs. Native-like Env trimers can induce autologous NAb responses against resistant (Tier-2) viruses in several animal models. Here we review recent studies aimed at addressing the challenge of driving the strong but narrowly focused NAb responses to Env trimers towards ones with much greater breadth. Among strategies that merit pursuing are using multiple trimers as sequential or simultaneous immunogens, targeting the germline precursors of bNAbs, delivering sequential lineages of trimers derived from infected individuals who developed bNAbs, and presenting trimers as particulate antigens.
READ MORE
|
|
|
|
Funding Opportunities
Public Health Agency of Canada
HIV and Hepatitis C Community Action Fund – Call for Letters of Intent
DEADLINE: APRIL 15, 2016 – 3:00 PM EASTERN TIME
The Public Health Agency of Canada is launching a call for Letters of Intent (LOI) for the HIV and Hepatitis C Community Action Fund (the Fund). The Community Action Fund has a total of $26.4 million available to support the community based response to HIV/AIDS, hepatitis C, and related sexually transmitted and blood borne infections (STBBI). The purpose of the Call for LOIs is to identify projects that align with the priorities and eligibility criteria of the Fund. Organizations with a successful LOI will then be invited by the Agency to submit a full proposal. An invitation to submit a full proposal does not represent a commitment on the part of the Agency to fund any or all proposed activities.
MORE INFORMATION
PEPFAR
DREAMS Innovation Challenge
DEADLINE: March 28, 2016
DREAMS is about investing in multiple solutions to one problem – HIV/AIDS. The 10 DREAMS countries account for nearly half of all the new HIV infections among adolescent girls and young women globally in 2014. The DREAMS partnership is delivering a Core Package of evidence-informed approaches that go beyond the health sector, addressing the structural drivers that directly and indirectly increase girls’ HIV risk, including poverty, gender inequality, sexual violence, and lack of education.
MORE INFORMATION
Gilead
HIV Cure
DEADLINE: MAY 1, 2016
Through the Corporate Grants program, Gilead intends to support the efforts of academic institutions, non-profit organizations and community groups engaged in activities related to suppressing or eliminating HIV without antiretroviral therapy. Specifically, Gilead is looking to support the following four areas: Translational Research, Efficacy Studies in Animal Models, Institutional Funding, and Community Groups.
MORE INFORMATION
Mitacs
Globalink Research Award
DEADLINE: JUNE 10, 2016
The Mitacs Globalink Research Award provides funding to support senior undergraduate and graduate student research projects abroad. The Award provides an opportunity for faculty at Canadian universities to strengthen existing international research collaborations and connect with colleagues around the world through the mobility of senior undergraduate and graduate students. Student recipients of the Globalink Research Award will develop research skills, cultural fluency, and professional networks, become part of Canada’s generation of global innovators.
MORE INFORMATION
|
|
|
|
Employment Opportunity
|
|
University of Manitoba
Assistant or Associate Professor, Department of Medical Microbiology
DEADLINE: MARCH 31, 2016 or until position is filled
The Department of Medical Microbiology in the College of Medicine, Faculty of Health Sciences, University of Manitoba, invites applications for one full-time tenure-track position at the rank of Assistant or Associate Professor in the Department of Medical Microbiology, beginning April 2017 or as soon thereafter as possible. The appointments will be at a salary commensurate with qualifications and experience.
MORE INFORMATION
|
|
|
|
Conferences
|
|
March 20 to 24, 2016
Keystone Symposia – HIV Persistence: Pathogenesis and Eradication (X7)
California, USA
|
|
March 20 to 24, 2016
Keystone Symposia – HIV Vaccines (X8)
California, USA
|
|
May 3 to 6, 2016
10th International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-Limited Settings (INTEREST Workshop 2016)
Cameroon, Africa
|
|
May 12 to 15 2016
CAHR 2016
Winnipeg, Canada
|
|
July 18 to 22, 2016
AIDS 2016
Durban, South Africa
|
|
July 25 to 26, 2016
ICHA 2016: International HIV and AIDS Conference
London, United Kingdom
|
|
October 17-20, 2016
HIV Research for Prevention
Chicago, USA
|
|
| |
You are receiving this email because you registered to receive news updates from the ACO
or you are a member of a
CHVI-funded
project team.
|
|
Annual Update
|
|
|
The Annual Report offers highlights of ACO activities over the past fiscal year. Read our 2014-2015 Annual Update.
|
White Paper
|
The ACO has developed a White Paper to foster effective coordination of key players across the Canadian HIV vaccine research landscape.
|
|
|
About Us
|
|
The ACO was established by the Government of Canada and the Bill & Melinda Gates Foundation in November 2011 at the International Centre for Infectious Diseases (ICID), a
not-for-profit,
non-governmental organization based in Winnipeg.
|
|
|
Address
|
|
ACO at
International Centre for Infectious Diseases
515 Portage Avenue
Winnipeg, MB, Canada
R3B 2E9
Tel.: 204 946 0908
Fax: 204 946 0927
email:
aco@icid.com
|
|
| |
|
Follow Us:
|
|
|
| |
| |
| |
| |
| |
|
